Mitophagy is a specialized form of autophagy[@abe1998] that involves the selective degradation of damaged or dysfunctional mitochondria. This process is critical for maintaining mitochondrial quality control and cellular homeostasis, particularly in post-mitotic cells such as neurons that cannot dilute damaged organelles through cell division. The term "mitophagy" was first coined by Professor Yoshino Abe and colleagues in 1998, describing the sequestration of mitochondria into autophagosomes during nutrient deprivation[@abe1998].
Neurons exhibit unique vulnerabilities that make mitophagy particularly crucial for their survival. As highly energy-demanding cells, neurons rely heavily on mitochondrial function to meet their metabolic needs, producing approximately 90% of their ATP through oxidative phosphorylation. The brain, while comprising only 2% of body weight, consumes approximately 20% of the body's total oxygen and energy resources. This high metabolic demand, combined with the long lifespan of neurons and their limited regenerative capacity, makes them exceptionally susceptible to mitochondrial dysfunction[@lin2006].
The importance of mitophagy in neuronal health is underscored by the fact that defective mitophagy has been directly implicated in the pathogenesis of numerous neurodegenerative disorders, including Parkinson's disease[@parkinsons], Alzheimer's disease[@alzheimers], and amyotrophic lateral sclerosis[@amyotrophic]. The accumulation of dysfunctional mitochondria is a hallmark feature observed in post-mortem brain tissue from patients with these disorders, suggesting that impaired mitophagy contributes to disease progression[@lin2006].
Mitochondrial dysfunction in neurodegeneration is characterized by several key features: impaired oxidative phosphorylation, increased production of reactive oxygen species (ROS), altered mitochondrial dynamics, and reduced ability to clear damaged mitochondria. These defects create a vicious cycle where accumulated mitochondrial damage further compromises cellular energy metabolism and increases oxidative stress, ultimately leading to neuronal death. The selective removal of damaged mitochondria through mitophagy represents a critical protective mechanism that prevents the accumulation of dysfunctional mitochondria and maintains neuronal viability.
The PINK1[@pink]-Parkin[@parkin] pathway represents the most well-characterized mechanism of mitophagy induction in response to mitochondrial damage. This pathway is particularly significant in the context of neurodegenerative diseases, as mutations in both PINK1 (PTEN-induced kinase 1) and Parkin genes cause autosomal recessive Parkinson's disease[@kitada1998].
Under normal conditions, PINK1 is constitutively imported into healthy mitochondria through the TOMM40[@tomm] (Translocase of Outer Mitochondrial Membrane 40) complex and degraded by proteases within the mitochondrial matrix. However, upon mitochondrial damage or loss of membrane potential, PINK1 fails to be imported and instead accumulates on the outer mitochondrial membrane[@narendra2008]. The accumulation of PINK1 on the mitochondrial surface serves as the initial signal for mitophagy initiation.
Once stabilized on the outer mitochondrial membrane, PINK1 undergoes autophosphorylation and then phosphorylates both ubiquitin and the ubiquitin-like domain of Parkin. This phosphorylation event activates Parkin's E3 ubiquitin ligase activity, leading to the ubiquitination of multiple outer mitochondrial membrane proteins[@koyano2014]. The ubiquitination of these proteins serves as a "eat-me" signal for the autophagy machinery.
The selective recognition of ubiquitinated mitochondria is mediated by autophagy receptors that contain both ubiquitin-binding domains and LC3-interacting regions (LIRs). Key receptors involved in PINK1-Parkin-mediated mitophagy include OPTN[@optn] (Optineurin), NDP52 (Nuclear Domain 10 Protein 2), and NBR1[@nbr] (Neighbor of Brca1 Gene 1). These receptors bridge the ubiquitinated mitochondria to the growing autophagosome by binding to LC3/GABARAP proteins on the phagophore membrane.
The OPTN[@optn] protein plays a particularly important role in mitophagy, and mutations in the OPTN gene have been linked to both glaucoma and amyotrophic lateral sclerosis[@maruyama2010]. OPTN contains an ubiquitin-binding domain (UBD) and a microtubule-binding domain that may help in the transport of damaged mitochondria to perinuclear regions where lysosomal fusion occurs.
In addition to the PINK1-Parkin pathway, neurons can also utilize receptor-mediated mitophagy, which involves direct binding of mitochondrial outer membrane proteins to LC3/GABARAP proteins. This pathway can be activated independently of Parkin and is particularly important under certain physiological conditions.
BNIP3 and NIX (BNIP3L)
BNIP3 (BCL2/adenovirus E1B 19kDa protein-interacting protein 3) and its homolog NIX (BNIP3-like, also known as BNIP3L) are mitophagy receptors that contain LIR motifs and can directly initiate mitophagy by binding to LC3[@novak2010]. These proteins are BH3-only members of the Bcl-2 family and can be induced under hypoxic conditions or during erythroid cell maturation.
The BNIP3/NIX pathway is particularly important in certain neuronal populations and during specific stress conditions. BNIP3 expression can be induced by hypoxia-inducible factor (HIF-1α), making this pathway critical for mitochondrial quality control during periods of reduced oxygen availability. NIX has been shown to play essential roles in mitochondrial clearance during reticulocyte maturation, and dysregulation of this pathway may contribute to neuronal death in various pathological conditions[@schweers2007].
FUNDC1
FUNDC1 (FUN14 domain containing 1) is another outer mitochondrial membrane protein that functions as a mitophagy receptor. It contains a LIR motif that interacts with LC3, and its activity is regulated by phosphorylation. FUNDC1 is particularly sensitive to hypoxia and has been implicated in mitophagy induced by hypoxic conditions[@liu2012]. The regulation of FUNDC1 through post-translational modifications, including phosphorylation and ubiquitination, provides additional layers of control for this mitophagy pathway.
The process of mitophagy is intimately connected to mitochondrial dynamics, involving the continuous cycles of mitochondrial fusion and fission. Mitofusin 1 (MFN1) and Mitofusin 2 (MFN2)[@mfn] are GTPases that mediate outer mitochondrial membrane fusion, while OPA1 mediates inner membrane fusion. The dynamin-related protein 1 (DRP1) mediates mitochondrial fission, facilitating the segregation of damaged mitochondrial segments for removal[@chan2020].
The PINK1-Parkin pathway actively regulates mitochondrial dynamics to facilitate mitophagy. Parkin-mediated ubiquitination of MFN2[@mfn] promotes its degradation, thereby inhibiting mitochondrial fusion and facilitating the segregation of damaged mitochondria[@gegg2010]. This fission step is essential for the selective removal of damaged mitochondrial components while preserving functional mitochondrial networks.
The interplay between mitochondrial dynamics and mitophagy ensures that only damaged portions of the mitochondrial network are targeted for degradation. The recruitment of autophagy receptors to damaged mitochondria is facilitated by the fission process, which creates discrete mitochondrial fragments that can be engulfed by the autophagosome.
NBR1[@nbr] is a selective autophagy receptor that participates in mitophagy alongside its well-established role in general autophagy. NBR1 contains an ubiquitin-binding domain and multiple LIR motifs, allowing it to recognize ubiquitinated mitochondria and deliver them to autophagosomes[@kirkin2009]. The cooperation between NBR1 and other receptors such as OPTN ensures robust mitophagy induction and efficient clearance of damaged mitochondria.
The link between mitophagy and Parkinson's disease[@parkinsons] represents one of the most compelling connections between mitochondrial quality control and neurodegeneration. The discovery that mutations in PINK1[@pink] and PARKIN[@parkin] cause autosomal recessive Parkinson's disease provided the first direct genetic evidence linking mitophagy to neurodegeneration[@kitada1998].
In sporadic Parkinson's disease, multiple mechanisms appear to compromise mitophagy function. Mitochondrial complex I deficiency, a consistent finding in PD brains, may lead to increased mitochondrial damage that overwhelms the mitophagy system. Additionally, alterations in autophagy-lysosomal pathway proteins have been reported in PD patient brains, including decreased levels of Beclin-1 and LC3-II[@dehay2010].
The PINK1-Parkin pathway appears to be particularly important for the survival of dopaminergic neurons in the substantia nigra pars compacta, the region most vulnerable in Parkinson's disease. These neurons have high metabolic demands and extensive axonal projections, requiring efficient mitochondrial turnover. Impairment of mitophagy in these neurons leads to the accumulation of dysfunctional mitochondria, increased oxidative stress, and ultimately neuronal death[@valente2004].
Alpha-synuclein, whose aggregation is a hallmark of Parkinson's disease, has been shown to directly inhibit mitophagy. Wild-type alpha-synuclein can bind to mitochondria and interfere with mitochondrial quality control mechanisms, while mutant forms of alpha-synuclein associated with familial PD show enhanced mitochondrial localization and increased detrimental effects[@poehler2014].
In Alzheimer's disease[@alzheimers], mitochondrial dysfunction occurs early in disease pathogenesis and contributes to synaptic failure and neuronal death. Multiple studies have documented impaired mitophagy in AD brains, with reduced expression of mitophagy-related proteins and decreased autophagic clearance of mitochondria[@kerr2017].
The amyloid-beta peptide, the primary constituent of amyloid plaques in AD, has been shown to directly impair mitochondrial function and mitophagy. Amyloid-beta accumulation in mitochondria leads to reduced mitochondrial membrane potential, increased ROS production, and impaired mitophagy[@manczak2006]. Additionally, tau pathology, the other hallmark of AD, has been associated with disrupted mitochondrial dynamics and transport.
Interestingly, the PINK1-Parkin pathway may be specifically impaired in Alzheimer's disease. Studies have shown decreased PINK1 and Parkin expression in AD brains, along with reduced phosphorylation of Parkin and its substrates[@du2017]. This impairment may contribute to the accumulation of damaged mitochondria observed in AD neurons.
The interplay between amyloid-beta and mitophagy creates a pathogenic cycle: amyloid-beta induces mitochondrial damage, while impaired mitophagy fails to clear damaged mitochondria, leading to further amyloid-beta production and aggregation. Therapeutic approaches aimed at enhancing mitophagy may therefore break this vicious cycle.
Amyotrophic lateral sclerosis[@amyotrophic] is a progressive neurodegenerative disorder affecting upper and lower motor neurons. Multiple genes linked to familial ALS encode proteins involved in autophagy and mitophagy, including OPTN, TBK1, and VCP[@taylor2016].
Mutations in the OPTN[@optn] gene cause a subset of familial ALS, and functional studies have demonstrated that these mutations impair mitophagy. OPTN mutations associated with ALS show reduced binding to ubiquitinated mitochondria and decreased recruitment to damaged mitochondria[@shen2011]. This defect leads to accumulation of dysfunctional mitochondria in motor neurons, contributing to the progressive neurodegeneration observed in ALS.
The TBK1 (TANK-binding kinase 1) gene, also linked to ALS, encodes a kinase that phosphorylates OPTN and other autophagy receptors, enhancing their activity. TBK1 mutations impair this phosphorylation event, compromising mitophagy efficiency[@richter2016]. Similarly, mutations in the VCP (Valosin-containing protein) gene, which encodes an AAA+ ATPase involved in autophagosome maturation, cause ALS and frontotemporal dementia.
Motor neurons appear to be particularly dependent on efficient mitophagy due to their large size, high metabolic demands, and specialized architecture. The selective vulnerability of motor neurons in ALS may therefore reflect their heightened requirement for mitochondrial quality control.
Huntington's disease is caused by CAG repeat expansion in the huntingtin (HTT) gene, leading to mutant huntingtin protein that accumulates in neurons and causes progressive neurodegeneration. Multiple studies have demonstrated impaired mitophagy in Huntington's disease models and patient tissue[@t2019].
Mutant huntingtin protein directly interferes with mitochondrial function and mitophagy through multiple mechanisms. It can sequester PINK1 and Parkin, preventing their recruitment to damaged mitochondria. Additionally, mutant huntingtin disrupts mitochondrial dynamics by altering the expression and localization of fission and fusion proteins[@shirendeb2011].
The autophagy receptor FUNDC1 has been implicated in mitophagy deficits in Huntington's disease. Studies have shown that FUNDC1 expression is reduced in HD models, and restoring FUNDC1 levels can improve mitophagy and neuronal survival[@guo2016]. These findings suggest that multiple pathways converge to impair mitophagy in Huntington's disease.
The identification of compounds that enhance mitophagy has become a major focus for drug development in neurodegenerative diseases. Several classes of small molecules have shown promise in preclinical studies.
Urolithin A
Urolithin A is a gut microbiome-derived metabolite that has been shown to enhance mitophagy in cellular and animal models. It stimulates the clearance of defective mitochondria through a mechanism involving the inhibition of mitochondrial death pathway signaling[@ryu2016]. Clinical trials of urolithin A have demonstrated safety and tolerability in humans, with ongoing studies in neurodegenerative diseases.
NAD+ Precursors
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), precursors of NAD+, have shown beneficial effects on mitochondrial function and mitophagy. NAD+ levels decline with age and in neurodegenerative diseases, and restoration of NAD+ can enhance sirtuin activity and mitochondrial quality control[@canto2015].
Natural Compounds
Several natural compounds with antioxidant properties have been investigated for their mitophagy-enhancing effects. Resveratrol, found in red wine grapes, activates SIRT1 and enhances mitophagy through a PINK1-Parkin-dependent mechanism[@wu2011]. Curcumin, the active compound in turmeric, has also been shown to promote mitophagy and reduce mitochondrial dysfunction in various models.
Gene therapy offers the potential to directly target mitophagy-related genes for neurodegenerative disease treatment.
PARK2 Gene Delivery
Viral vector-mediated delivery of the PARKIN gene has been explored in preclinical models of Parkinson's disease. Studies in PINK1 knockout mice demonstrated that Parkin overexpression could restore dopaminergic neuron survival[@yasuda2011]. However, the timing of intervention appears critical, as overexpression in established disease may have limited benefit.
Targeting Autophagy Receptors
Enhancing the expression or function of autophagy receptors such as OPTN and NBR1 represents another therapeutic strategy. Gene therapy approaches to increase OPTN expression have shown promise in cellular models of ALS[@abramov2016].
Given the intimate connection between mitochondrial dynamics and mitophagy, targeting fission and fusion proteins has emerged as a therapeutic approach.
DRP1 Inhibitors
Mdivi-1, a selective inhibitor of DRP1, has been shown to reduce mitochondrial fission and improve mitochondrial function in models of Parkinson's disease[@rappold2014]. However, the complete inhibition of fission may have adverse effects, as some fission is necessary for proper mitochondrial quality control.
MFN2 Activators
Small molecules that enhance MFN2 function or expression may promote mitochondrial fusion and improve overall mitochondrial quality. However, excessive fusion can also be detrimental, as it prevents the segregation of damaged mitochondrial components.
The development of biomarkers for mitophagy is crucial for patient stratification and monitoring therapeutic responses. Several approaches are being investigated.
Mitochondrial DNA Copy Number
Alterations in mitochondrial DNA (mtDNA) copy number have been observed in neurodegenerative diseases and may reflect compensatory responses to mitochondrial dysfunction. Elevated mtDNA copy number in peripheral blood cells has been reported in Parkinson's disease patients[@pyle2020].
Circulating Mitochondrial Proteins
Plasma levels of mitochondrial proteins, including mitochondrial DNA and specific mitochondrial lipids, are being evaluated as minimally invasive biomarkers. The release of mitochondrial components into circulation may reflect tissue-specific mitochondrial damage and impaired clearance.
Functional Assessments
Biochemical and functional assessments of mitophagy flux in patient-derived cells provide direct measures of mitophagy efficiency. The generation of induced pluripotent stem cells (iPSCs) from patient fibroblasts allows for detailed characterization of mitophagy in disease-relevant cell types[@imaizumi2012].
Several clinical trials are currently investigating mitophagy-targeted therapies in neurodegenerative diseases.
Trials of NAD+ precursors, including nicotinamide riboside, are underway in Parkinson's disease and Alzheimer's disease. These trials aim to evaluate the effects of NAD+ augmentation on mitochondrial function and clinical outcomes[@canto2015].
Urolithin A has progressed to clinical testing in various populations, including studies in older adults and patients with mild cognitive impairment. Preliminary results suggest improvements in mitochondrial biomarkers[@ryu2016].
Gene therapy approaches for Parkinson's disease targeting PINK1 or PARKIN have been explored in early-phase clinical trials. However, delivery to the appropriate brain regions and achieving sufficient expression levels remain technical challenges.
Several challenges must be addressed to successfully translate mitophagy-based therapies to the clinic. The complexity of mitophagy regulation, with multiple parallel pathways, suggests that combination approaches targeting several mechanisms may be more effective than single-target interventions. Additionally, the timing of intervention may be critical, as mitophagy enhancement in early disease stages may be more beneficial than in established neurodegeneration.
The development of biomarkers that can predict treatment response and monitor disease progression will be essential for personalized therapeutic approaches. The identification of patient subgroups with specific mitophagy defects may enable targeted interventions.
Future research directions include the exploration of age-related changes in mitophagy and how these may contribute to late-onset neurodegeneration. The development of more sophisticated models, including patient-derived neurons and brain organoids, will provide better platforms for drug screening and mechanistic studies.
The following diagram shows the key molecular relationships involving Mitophagy Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: